Anti-dinitrophenyl antibody (Anti-DNP)

Anti-dinitrophenyl (DNP) antibodies are specialized immunoglobulins that bind to the synthetic hapten 2,4-dinitrophenyl (PubChem CID 5460671). Because DNP is not found naturally in humans, these antibodies serve as a highly specific tool in both basic immunology and advanced therapeutic engineering (Kim et al., 2015). In research, they are widely used to model allergic reactions and study B-cell signaling through the use of DNP-conjugated proteins. In the context of modern oncology, anti-DNP antibodies are central to adapter-based or universal chimeric antigen receptor (CAR) T-cell therapies (Ma et al., 2016). In this approach, a patient is administered a DNP-conjugated adapter molecule that targets a specific tumor antigen, and anti-DNP CAR-T cells then recognize and eliminate the tagged cells. This modular system allows for tunable activity and the ability to target multiple antigens with a single cell product. Additionally, DNP-conjugated tumor vaccines have been investigated for their ability to increase the immunogenicity of tumor-associated antigens, thereby stimulating a more robust endogenous anti-tumor response (Berd et al., 1991).

Other names

Anti-2,4-dinitrophenyl antibodyAnti-DNP antibodyAnti-DNP IgEAnti-DNP IgGAnti-dinitrophenyl immunoglobulin

Adapter-mediated recruitment of immune effector cells to hapten-labeled targets, where the antibody or a CAR-T cell recognizes the DNP moiety on a bridge molecule bound to a tumor cell.